Novartis and Abogen: RNA license for up to 7.2 billion

Context

In brief

• Novartis obtains worldwide license on ABO2203.
• Abogen receives an initial $575 million.
• The agreement can reach about 7.2 billion.
• ABO2203 mRNA is used against B lymphocytes.

Key Facts

• Active ingredient: ABO2203
• License: Worldwide Exclusive
• Initial payment: $575 million
• Value: CHF 480 million
• Potential: up to approximately $7.2 billion
• Technology: mRNA
• Development: clinical phase

The structure of the agreement

Novartis expands its portfolio of RNA-based therapeutics thanks to a license agreement with Abogen Biosciences, a Chinese biotech company. The agreement was communicated by Abogen itself in a note.

At the heart is ABO2203, a new active ingredient for the treatment of autoimmune diseases. The agreement gives Novartis an exclusive worldwide license on the active ingredient and provides options on additional drug programs based on Abogen's RNA platform.

The expected initial payment for Abogen is $575 million, or CHF 480 million. The potential portion of the transaction can be as high as $7.2 billion if all options on the other programs are exercised and the respective development, approval and commercialization milestones are met.

Abogen will also be entitled to possible licensing revenue on future sales of the products. The structure therefore combines an initial component, a part related to milestones and a possible return on sales.

How does ABO2203

ABO2203 uses mRNA, the messenger ribonucleic acid, to induce the body to produce a molecule on its own that attacks and eliminates B lymphocytes in a targeted manner. These cells play an important role in many autoimmune diseases. According to Abogen, the drug is already in clinical development.

RNA technology had made a lot of headlines especially thanks to the Covid vaccines from Moderna and Biontech. However, it has existed for several decades and had previously been tested mainly in cancer research. The press release thus puts in the same agreement an active ingredient already in clinical development and a platform from which other programs can derive.

Operational details

What does potential value mean

To read the agreement from an economic point of view, it is necessary to keep separate the initial payment, the conditions for subsequent payments and the possible revenues related to sales. The figure of about 7.2 billion is not presented as an initial outlay: the source links it to the exercise of all options and the achievement of the expected goals.

The components of the agreement

The correct comparison is therefore not between two sums available at the same time. The $575 million is reported as the initial payment; instead, the maximum value depends on a sequence of conditions. All options for the other programs must be exercised first, then the respective development, approval, and commercialization milestones must be met.

For a reader in Switzerland, the reference to 480 million francs makes the scale of the initial component immediate, while the total potential remains expressed in dollars. The currency, however, does not change the structure of the agreement: the first amount and the maximum potential belong to different times and conditions.

The scientific profile must also be read separately from the commercial one. ABO2203 is described as already in clinical development, but the agreement also links additional payments to approval and marketing. The text therefore distinguishes the development of the drug from the steps necessary to get to sales.

For the daily life of residents, the concrete connection remains informative: the source describes a transaction between companies, not a payment intended for families. To distinguish the company figure from one's income, you can use the calcolatore stipendio; those who want to follow the labor market can consult the aziende che assumono.

Useful tools to protect your net income

To reduce FX leakage, compare CHF-EUR exchange options and banks for cross-border workers.

Key points

A control board for the reader

Five operational steps

1. Identify the object. The first reference is ABO2203, an active ingredient intended for the treatment of autoimmune diseases. This avoids confusing it with the broader RNA-based platform.

2. Separate license and options. The license granted to Novartis is exclusive and worldwide for ABO2203. The options instead cover additional drug programs based on Abogen's RNA platform.

3. Record the amount and currency. The initial payment should be recorded as 575 million dollars, with the indicated equivalent of 480 million francs. The two figures describe the same initial payment, not two separate payments.

4. Rebuild the condition for the maximum. The value of up to about $7.2 billion requires the exercise of all options and the achievement of development, approval and commercialization goals. The figure should therefore be read as a scenario subject to these steps.

5. Keep future sales separate. Abogen may have possible license revenue on future product sales. This item should not be confused with either the initial payment or the milestones listed above.

The reading procedure allows you to update the news without adding external estimates. Each new element should be traced back to one of five steps: the active ingredient, options, initial amount, milestones or future sales.

On a scientific level, two pieces of information from the source remain central: ABO2203 mRNA is used to target B lymphocytes and the drug is already in clinical development. On the economic level, however, the decisive fact is the distinction between the initial payment and payments subject to subsequent phases.

To keep the agreement data separate from your income, use the calcolatore stipendio.

Source: swissinfo.ch